Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12

References

• Al Robaian M, Chiam KY, Blatchford DR, Dufès C. (2014). Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas. Nanomedicine 9:421–34.
   PubMed Web of Science ®Google Scholar
• Aldawsari H, Edrada-Ebel R, Blatchford DR, et al. (2011). Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex. Biomaterials 32:5889–99.
   PubMed Web of Science ®Google Scholar
• Barresi G, Tuccari G. (1984). Lactoferrin in benign hypertrophy and carcinomas of the prostatic gland. Vichows Archiv A Pathol Anat 403:59–66.
   Google Scholar
• Eisenauer EA, Therasse P, Bogaerts J, et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–47.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–86.
   PubMed Web of Science ®Google Scholar
• Fujita T, Timme TL, Tabata K, et al. (2007). Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther 14:227–36.
   PubMed Web of Science ®Google Scholar
• Futaki S, Ohashi W, Suzuki T, et al. (2001). Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjugate Chem 12:1005–11.
   PubMed Web of Science ®Google Scholar
• Gabaglia CR, DeLaney A, Gee J, et al. (2010). Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice. J Transl Med 8:1–10.
   PubMed Web of Science ®Google Scholar
• Gately MK, Renzetti LM, Magram J, et al. (1998). The interleukin-12/interleukin-12 receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16:495–521.
   PubMed Web of Science ®Google Scholar
• Gibbons JA, Kanwar RK, Kanwar JR. (2011). Lactoferrin and cancer in different cancer models. Front Biosci 2:1080–8.
   Google Scholar
• Hermanson GT. 2013. Bioconjugate Techniques. 3rd ed. London: Elsevier Inc.
   Google Scholar
• Honary S, Zahir F. (2013). Effect of zeta potential on the properties of nano-drug delivery systems: a review (Part 2). Trop J Pharm Res 12:265–73.
   Web of Science ®Google Scholar
• Jiang RL, Lopez V, Kelleher SL, Lonnerdal B. (2011). Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol 226:3022–31.
   PubMed Web of Science ®Google Scholar
• Kaliberov SA, Kaliberova LN, Stockard CR, et al. (2004). Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. Mol Ther 10:1059–70.
   PubMed Web of Science ®Google Scholar
• Kim TI, Baek JU, Bai CZ, Park JS. (2007). Arginine-conjugated polypropylenimine dendrimer as a non-toxic and efficient gene delivery carrier. Biomaterials 28:2061–7.
   PubMed Web of Science ®Google Scholar
• Kim HR, Gil S, Andrieux K, et al. (2007b). Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 64:356–64.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, et al. (1997). Effects of single-dose interleukin-12 exposure on interleukin -12 associated toxicity and interferon-gamma production. Blood 90:2541–8.
   PubMed Web of Science ®Google Scholar
• Lim LY, Koh PY, Somani S, et al. (2015). Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. Nanomed Nanotech Biol Med 11:1445–54.
   PubMed Web of Science ®Google Scholar
• Liu J, Shapiro JI. (2003). Endocytosis and signal transduction: basic science update. Biol Res Nurs 5:117–28.
   PubMedGoogle Scholar
• Lu Y. (2009). Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv. Drug Del Rev 61:572–88.
   PubMed Web of Science ®Google Scholar
• Lucas ML, Heller L, Coppola D, Heller R. (2002). IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16F10 melanoma. Mol Ther 5:668–75.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Szegezdi E, Keane M, et al. (2009). TRAIL receptor signaling and modulation: are we on the right TRAIL? Cancer Treat Rev 35:280–8.
   PubMed Web of Science ®Google Scholar
• Mahato RI, Smith LC, Rolland A. (1999). Pharmaceutical perspectives of nonviral gene therapy. Adv Genet 41:95–156.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Rossi CR, Pilati P, Nitti D. (2005). Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35–53.
   PubMed Web of Science ®Google Scholar
• Nasu Y, Bangma CH, Hull GW, et al. (2001). Combination gene therapy with adenoviral vector-mediated HSV-tk + GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis 4:44–55.
   PubMed Web of Science ®Google Scholar
• Rokhlin OW, Bishop GA, Hostager BS, et al. (1997). Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 57:1758–68.
   PubMed Web of Science ®Google Scholar
• Saman DM, Lemieux AM, Lutfiyya MN, Lipsky MS. (2014). A review of the current epidemiology and treatment options for prostate cancer. Dis Mon 60:150–4.
   PubMed Web of Science ®Google Scholar
• Somani S, Robb G, Pickard BS, Dufès C. (2015). Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex. J Control Release 217:235–42.
   PubMed Web of Science ®Google Scholar
• Tannenbaum CS, Tubbs R, Armstrong D, et al. (1998). The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161:927–32.
   PubMed Web of Science ®Google Scholar
• Tuccari G, Barresi G. (2011). Lactoferrin in human tumours: immunohistochemical investigations during more than 25 years. Biometals 24:775–84.
   PubMed Web of Science ®Google Scholar
• van Ophoven A, Ng CP, Patel B, et al. (1999). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Prostate Cancer Prostatic Dis 2:227–33.
   PubMed Web of Science ®Google Scholar
• Varghese S, Rabkin SD, Liu R, et al. (2006). Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 13:253–65.
   PubMed Web of Science ®Google Scholar
• Visser CC, Stevanović S, Voorwinder H, et al. (2004). Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target 12:145–50.
   PubMed Web of Science ®Google Scholar
• Wei M, Xu Y, Zou Q, et al. (2012). Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci 46:131–41.
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumura D, et al. (1995). Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–6.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zeng Z, Zhang W, et al. (2008). Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer 123:2065–72.
   PubMed Web of Science ®Google Scholar
• Zinselmeyer BH, Mackay SP, Schätzlein AG, Uchegbu IF. (2002). The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res 19:960–7.
   PubMed Web of Science ®Google Scholar